Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
14.84
-1.10 (-6.93%)
At close: Jun 17, 2025, 4:00 PM
14.70
-0.14 (-0.91%)
After-hours: Jun 17, 2025, 7:37 PM EDT
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$2,112
Profits / Employee
-$1,699,986
Market Cap
1.21B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VRDN News
- 8 days ago - Viridian Therapeutics: The Song Remains The Same - Seeking Alpha
- 12 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
- 4 weeks ago - Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - Business Wire
- 5 weeks ago - Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - Business Wire
- 6 weeks ago - Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Business Wire
- 2 months ago - Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Business Wire
- 3 months ago - Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha